54 results about "CD80" patented technology

A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.

A method for generating or expanding a population of natural killer cells (NK cells) via using modified K562 feeder cells having expression of factors capable of increasing activation and proliferation of natural killer cells, wherein the factors capable of increasing activation and proliferation of NK cells include: (A) a co-stimulatory molecule comprises CD80 molecules, and 4-1BBL molecules; and (B) a cytokine, specifically membrane-bound IL-21 (mbIL-21).

The invention belongs to the field of biological medicine, and discloses a membrane binding type IL7 fusion protein, an engineered immune cell for expressing the membrane binding type IL7 fusion protein and application of the membrane binding type IL7 fusion protein. The fusion protein comprises an IL7 region and a transmembrane domain and can be expressed on a cell membrane, the tumor cell killing ability and the T cell survival ability of T cells expressing the fusion protein are both enhanced, and the aims of improving the tumor immune cell treatment effect and reducing the toxic and side effects are achieved. Particularly, the IL7 fusion protein anchors and expresses IL7 on the surface of a cell through transmembrane domains such as CD80 or PD-L1 and the like, so that (1) immune cells can be accurately regulated and controlled, the possibility that an excessive IL7 signal possibly causes autoimmune response or aggravates CRS is reduced, and the safety of the IL7 to immune cells such as T cells and the like is enhanced; (2) the half-life period of IL7 is prolonged, and the anti-tumor effect of adoptive immune cells is enhanced; and (3) the transmembrane fragment is linked with the IL7 through a hinge region of the flexible linker G4S, CD80 or PD-L1, so that the flexibility of the IL7 is enhanced, and the proliferation and killing functions of the IL7 on T cells are enhanced.

Provided is an anti-PD-L1 antigen binding protein, capable of binding to primate-derived PD-L1 with a KD value of 1×10−8 M or less. The antigen binding protein can block the binding of PD-1 and CD80 to PD-L1, stimulate the secretion of cytokines in immune cells, and can inhibit tumor growth and / or tumor cell proliferation. Also provided is a fusion protein, comprising human TGFBRII or a fragment thereof and the antigen binding protein. Also provided is an application of the antigen binding protein and / or the fusion protein in the prevention and treatment of tumors or cancers.

The present invention relates to antigen-binding proteins, related fragments thereof, for binding to CD80, and their use for treating various conditions such as inflammation and autoimmunity.

To provide an allogeneic tumor cell vaccine.SOLUTION: Provided is an allogeneic tumor cell vaccine, comprising: (1) a population of proliferation-incompetent, live, genetically engineered tumor cells expressing one or more tumor-specific antigens, the population comprising at least three stably expressed immunomodulatory molecules, at least three immunomodulatory molecules being OX40 ligand (OX40L), CD27 ligand (CD70), and CD28 ligand (CD28L) including CD80, CD86, or both, to induce one or more subpopulations of PBMCs to proliferate in response to the expressed immunomodulatory molecules and subsequently enter an effector phase to kill tumor cells, and the subpopulations of PBMC cells comprising one or more of T lymphocytes, natural killer (NK) cells, dendritic cells (DCs), or B lymphocytes; and (2) a pharmaceutically acceptable carrier.SELECTED DRAWING: None

The present invention provides a novel peptide, usages thereof and pharmaceutical composition having the same. The novel peptide is a first peptide. The pharmaceutical composition comprises the novel peptide and drug carriers, each novel peptide is connected to the surface of the drug carrier by a linker. The amino acid sequence of the first peptide is shown in SEQ ID NO: 1. The first peptide can bind to CD80 protein, besides, the present invention proves that the novel peptide of the present invention achieves the efficiency of enhancing cell uptake.

The invention belongs to the technical field of vaccines, and particularly relates to a manganese-based platelet carrier vaccine based on a biomimetic mineralization technology and application of the manganese-based platelet carrier vaccine in immunotherapy. A manganese-based shell is deposited on the surface of a platelet, immunocompetence molecules such as CD40L and PF4 are expressed on the surface of the platelet, dendritic cells (DC) can be activated by directly contacting or secreting cell factors, and antigen presentation is promoted; in addition, deposited manganese ions can activate a cGAS-STING pathway, and meanwhile, CD40 / CD80 / CD86 / MHC-II costimulatory molecular expression on the surface of the DC is up-regulated. The vaccine adjuvant provided by the invention can be used for loading an antigen to form a three-in-one vaccine complex of the antigen (loaded on a platelet membrane), the platelet and a manganese shell, so that not only is the natural targeting capability of the platelet retained, but also DC cross presentation is enhanced through continuous release of manganese ions, finally CD8 + T cells are synergistically activated to react with an antibody, and the immune response of the antigen is enhanced. The antiviral immune response of the body is enhanced.

The invention relates to the technical field of cellular immunotherapy, in particular to application of drafenib mesylate in preparation of a dendritic cell (DCs) immunologic adjuvant. The invention provides an application of drafenib mesylate in preparation of a dendritic cell immunologic adjuvant. It is found that darfenib mesylate can promote the maturation and migration functions of DCs, and the migration ability of DCs is remarkably improved. The DCs activation aspect of the darfenib mesylate comprises improvement of expression of maturation indexes CD80, CD40 and CD86 and expression of a migration index CCR7. Darrafenib mesylate used in the invention is a chemotherapeutic drug approved by FDA for clinical treatment of patients with BRAF V600 mutation positive non-resectable or metastatic melanoma, the application of Darrafenib mesylate in immunotherapy is discovered, new use of old drugs is realized, and the Darrafenib mesylate has significant economic value.

An anticancer agent is provided comprising, as active ingredients, NK cells and a fusion protein comprising an IL-2 protein and a CD80 protein. In one specific formulation, a fusion protein comprising a CD80 fragment, an immunoglobulin Fc region, and an IL-2 variant can activate immune cells such as natural killer cells. Furthermore, since the pharmaceutical composition can effectively inhibit cancer, when co-administered with natural killer cells, it increases immune activity in the body, making it effective for cancer treatment and thus highly applicable to industry.

The application discloses an antigen-engineered nanovesicle vaccine (AN-FV) and a preparation method and application thereof. The vaccine is formed by fusion of vesicles of tumor cell membranes obtained by pretreatment of functionalized nanometer preparations and vesicles of mature dendritic cell membranes; the functionalized nanometer preparations contain autophagy inhibiting siRNA and an immunogenicity enhancer, and can synergistically improve MHC-I expression of tumor cells and antigen immunogenicity. The vaccine of the application simultaneously presents high-density MHC-I-antigen peptide complexes and CD80 / CD86 costimulatory molecules on the surface of a single particle, simulates an immune synapse in a nanometer scale, and thus efficiently activates tumor-specific T cells. The vaccine integrates antigen source engineering, physiologicalization of costimulatory signals and nanometer platform integration, and provides a new scheme for overcoming the treatment bottleneck of immune "cold" tumors such as pancreatic cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to application of crizotinib in induction of tolerant dendritic cells (tDCs). The invention provides an application of crizotinib in induction of tolerant dendritic cells. It is found that crizotinib can serve as an efficient inducer of tDCs, the activation state of DCs can be remarkably inhibited, the maturation function of DCs can be inhibited, the immune stimulation capacity of DCs can be reduced, then activation of T cells is inhibited, and therefore the crizotinib plays a role in treating immune diseases such as GVHD. In the invention, the inhibition of crizotinib on DCs comprises reduction of expression of maturation indexes CD80, CD40 and CD86. The crizotinib used in the invention is an ALK / ROS1 inhibitor approved by FDA and is mainly used for treating non-small cell lung cancer, the application of the crizotinib in immunotherapy is found, new use of old medicines is realized, and the crizotinib has great economic value.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).

The application relates to the field of biological medicines, and discloses a tumor vaccine containing a polysaccharide adjuvant and application thereof. The tumor vaccine formula comprises, in terms of mass fractions, 100 parts of WT1-CM-betaG NPs, 10 parts of astragalus polysaccharide, 5 parts of quillaja saponin and 1 part of a TLR agonist. The WT1-CM-betaG NPs comprise, in terms of mass fractions, 10 parts of a WT1 polypeptide combination, 50 parts of carboxymethylated beta-glucan nanoparticles CM-betaG NPs, 10 parts of EDC and 6 parts of NHS. The WT1 polypeptide is covalently connected to the carboxymethylated beta-glucan nanoparticles through chemical coupling, and then cooperates with the adjuvant, has a synergistic effect on improving the ability of stimulating DC maturation (high expression of CD80 / CD86 / MHC-II) and improving the secretion of key Th1 type cytokine IL-12p70, can improve the antitumor effect, and has a wide application in treating WT1 positive tumors.

The invention relates to the field of biological medicine, and discloses a tumor vaccine containing a polysaccharide adjuvant and application of the tumor vaccine, and the tumor vaccine is prepared from, by mass, 100 parts of WT1-CM-beta G NPs, 10 parts of astragalus polysaccharide, 5 parts of saponin and 1 part of TLR agonist. The WT1-CM-beta G NPs is prepared from the following components in parts by mass: 10 parts of a WT1 polypeptide combination, 50 parts of carboxymethylated beta-glucan nano CM-beta G NPs, 10 parts of EDC (Ethylene Dichloride) and 6 parts of NHS (N-Hydroxysuccinimide). The WT1 polypeptide is covalently linked to the carboxymethylated beta-glucan nanoparticles through chemical coupling, then the WT1 polypeptide and the carboxymethylated beta-glucan nanoparticles cooperate with the adjuvant, the WT1 polypeptide and the carboxymethylated beta-glucan nanoparticles have a synergistic effect on improving the capability of stimulating DC maturation (highly expressing CD80 / CD86 / MHC-II) and improving the secretion of key Th1 type cell factors IL-12p70, can improve the anti-tumor effect, and have wide application in treating WT1 positive tumors.

Provided herein are particles containing a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors such as lentiviral vectors containing the same, cells containing the same, and methods for using the same. The particle may be a lentiviral particle that displays a fusion molecule containing a) the CD58 extracellular domain or a functional fragment thereof, b) an antigen-binding fragment of an anti-CD3 antibody, and c) the CD80 or CD86 extracellular domain or a functional fragment thereof, and a viral glycoprotein (G protein) on the surface of the particle.

This invention belongs to the field of biomedical technology, specifically relating to the application of crizotinib in inducing tolerant dendritic cells (tDCs). This invention provides the application of crizotinib in inducing tolerant dendritic cells. This invention discovers that crizotinib can act as a highly effective inducer of tDCs, significantly inhibiting the activated state of DCs, suppressing their maturation function, reducing their immunostimulatory capacity, and thus inhibiting T cell activation, thereby exerting a therapeutic effect in immune diseases such as GVHD. The inhibitory effects of crizotinib on DCs in this invention include reducing the expression of maturation markers CD80, CD40, and CD86. The crizotinib used in this invention is an FDA-approved ALK / ROS1 inhibitor, primarily used for the treatment of non-small cell lung cancer. This invention discovers its application in immunotherapy, realizing the repurposing of an existing drug, and has significant economic value.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

CD38 is expressed on malignant plasma cells. CD28 is a costimulatory molecule required for T-cell activation and survival. Provided herein are novel anti-CD38 antibodies, anti-CD28 antibodies, and bispecific antibodies (bsAbs) that bind to both CD38 and CD28 and act as costimulatory agents to activate T cells via binding CD80 and / or CD86. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD38. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced CD38-targeted immune response is desired and / or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including multiple myeloma, lymphoma, and leukemia.

The present application provides a pharmaceutical composition for preventing or treating cancer, including, as an active ingredient, a fusion protein dimer including an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor. In one embodiment, the fusion protein including a CD80 fragment, an Fc domain of an immunoglobulin, and an IL-2 variant can activate immune cells such as natural killer cells, and control immune cell regulatory activity of regulatory T cells. Furthermore, the combined administration of the fusion protein and an immune checkpoint inhibitor such as Keytruda known as a PD-1 inhibitor can be effective in inhibiting cancer. Accordingly, the pharmaceutical composition provided by the present application including, as an active ingredient, a fusion protein dimer including an IL-2 protein or a variant thereof and a CD80 protein or a fragment thereof, and an immune checkpoint inhibitor can be effectively used for the treatment of cancer, and has a high degree of industrial applicability.

The present invention relates to the field of biomedicine. Provided are a monoclonal antibody targeting human HHLA2, and a multifunctional fusion antibody molecule derived therefrom. The HLLA2 monoclonal antibody can bind to an HLLA2 antigen with high specificity, and effectively block an immunosuppressive signaling pathway between the antigen and a receptor KIR3DL3, thereby relieving the functional inhibition of T cells and enhancing the tumor-killing function of NK cells. On the basis of the antibody scaffold, a fusion antibody comprising a plurality of immunomodulatory domains is constructed, wherein the domains comprise, but are not limited to, an anti-PD-L1 antibody or anti-PD-1 antibody or anti-CD3 antibody domain, a CD86 / CD80 variant polypeptide, and an LAG3 variant polypeptide. The fusion antibody can synergistically block a plurality of immune checkpoint pathways, activate costimulatory signals, promote maturation of antigen-presenting cells, and enhance activation and killing functions of T cells. The provided antibody molecule can be used for preparing immunotherapy drugs for a variety of indications, is especially suitable for the treatment of solid tumors or hematologic tumors, and thus has significant application potential in terms of enhancing anti-tumor immune responses.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

The invention provides application of a traditional Chinese medicine composition in preparation of a medicine for delaying senescence. The traditional Chinese medicine composition is prepared from traditional Chinese medicinal materials including ginseng, rhizoma polygonati, rhizoma atractylodis, radix sophorae flavescentis, radix ophiopogonis, rehmannia, polygonum multiflorum, dogwood, poria cocos, eupatorium, coptis chinensis, rhizoma anemarrhenae, herba epimedii and the like. Experiments prove that the pharmaceutical composition can significantly reduce the expression of P16, P21, TP53BP1 and gamma-H2AX in pancreas, reduce the content of TNF-alpha, IL-6 and IL-1beta in pancreas, reduce the number of pro-inflammatory immune cells CD80 +, CD4 + and CD8 + in pancreas, increase the number of anti-inflammatory immune cells CD206 + in pancreas, and delay pancreas aging.

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.